معرفی
Garry McDowell serves as a Reader in Clinical Biochemistry within the Department of Pharmacy and Biomolecular Sciences at Liverpool John Moores University's Faculty of Science. His research bridges clinical biochemistry and cardiovascular medicine with a strong focus on biomarker validation for risk stratification.
His primary research interests center on cardiovascular biomarkers for hypertension-mediated organ damage, atrial fibrillation complications, and kidney-heart interactions. He employs both traditional epidemiological methods and advanced machine learning techniques to analyze large datasets from global federated health networks. Key areas include sarcopenia-cardiovascular risk relationships, vitamin D's role in multiple sclerosis cardiovascular outcomes, and oxidative stress in cardiometabolic syndromes.
Analysis of his recent publications reveals a consistent pattern of biomarker-focused research applied across diverse patient populations including hemodialysis patients, stroke cohorts, and ethnic-specific atrial fibrillation registries. His work frequently leverages real-world data from international collaborations like the TriNetX network.
His research has been supported through collaborative projects involving major federated health databases, though specific grant details aren't visible in the provided text. He regularly collaborates with leading cardiovascular researchers including Gregory Y.H. Lip across multiple institutions.
McDowell maintains active involvement in clinical cardiology research through the TARGET consortium developing virtual twin technology for stroke management in atrial fibrillation, reflecting his commitment to translating biomarker research into personalized clinical applications.